Ernexa Therapeutics’ “Trojan Horse” stem cells can infiltrate ovarian tumors in mice, boosting T cell activity and leading to ...

The Trump administration's proposed funding cuts to the National Institutes of Health (NIH), including the National Cancer ...

The clinical trial tech companies Medidata and Medable are both taking to the floor of the American Society of Clinical ...

The founder of 23andMe, Anne Wojcicki, has asked a federal bankruptcy court judge to reopen an auction for the genetic ...

Bristol Myers Squibb is paying BioNTech $3.5 billion to board the PD-1/L1xVEGF-A bandwagon. The deal, which features up to $7 ...

Sanofi paid $55 million to partner with the biotech in 2019 and handed over a further $22 million to expand the collaboration ...

The first half of this year been riddled with market volatility and geopolitical tension. But 2025’s American Society of ...

Despite being more likely to be diagnosed with triple negative breast cancer (TNBC), Black women remain underrepresented in ...

The latest results, which J&J shared at the 2025 American Society of Clinical Oncology (ASCO) annual meeting in Chicago this ...

AstraZeneca has produced some fresh data to back up its blockbuster ambitions for camizestrant, tying the oral SERD to a 56% ...

In conversation with Fierce Biotech’s Chris Hayden, Austin Read, head of PPD™ CorEvitas™ Precision Medicine, Thermo Fisher ...

Regeneron isn’t the only Big Pharma to spot potential in Hansoh’s obesity pipeline. Merck & Co. ended last year paying $112 ...